肝纤维化表现为炎症细胞浸润、肝星状细胞激活、细胞外基质沉积及瘢痕组织形成，是各类慢性肝病向各类终末期肝病转变的关键病理过程。近年来，中医药被证明在防治肝纤维化方面成果突出，中医学对肝纤维化具有极富特色的诊疗理念，认为肝纤维化基本证候病机中“虚损”为其根本，并集中表现为气虚络瘀、肝郁脾虚和肝肾阴虚等证型，通过对以上3种常见肝纤维化证型总结相应常用效验方剂的临床及药理学研究进展，归纳其调控肝星状细胞命运、调节胆汁酸代谢、促进细胞外基质降解、抑制肝窦内皮血管化等潜在作用机制，为临床防治肝纤维化提供新思路。

Hepatic fibrosis is characterized by inflammatory cell infiltration, hepatic stellate cell activation, extracellular matrix (ECM) deposition, and scar tissue formation, which is the key pathological process for the transformation of various chronic liver diseases to end-stage liver diseases. In recent years, many studies have reported the outstanding achievements of traditional Chinese medicine in the prevention and treatment of liver fibrosis. TCM also has a very distinctive diagnosis and treatment concept for liver fibrosis, which considers "deficiency" as the basic syndrome and pathogenesis of liver fibrosis, and focuses on qi deficiency and collateral stasis, liver depression and spleen deficiency and liver-kidney yin deficiency. According to the three common syndrome types above, their modern pharmacological research progress, corresponding commonly used prescriptions and clinical efficacy and potential pharmacological mechanisms including regulating the fate of HSCs, regulating bile acid metabolism, promoting ECM degradation, and reducing angiogenesis are summarized, providing new ideas for clinical application of traditional Chinese medicine in treatment of liver fibrosis.

R285

国家自然科学基金资助项目（82274186）